Related references
Note: Only part of the references are listed.Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
Ludwig Kappos et al.
JOURNAL OF NEUROLOGY (2013)
Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: Illustration over a 20-year period
Stephanie Clisant et al.
CONTEMPORARY CLINICAL TRIALS (2012)
Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis
Richard Nicholas et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
The quality of reports of randomized trials in multiple sclerosis: a review
Alessio Signori et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data
Jan-Patrick Stellmann et al.
PLOS ONE (2012)
Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design
Richard Nicholas et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
The changing demographic pattern of multiple sclerosis epidemiology
Nils Koch-Henriksen et al.
LANCET NEUROLOGY (2010)
Assessing changes in relapse rates in multiple sclerosis
Seidu Inusah et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Relapses in multiple sclerosis are age- and time-dependent
H. Tremlett et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Regression to the mean in multiple sclerosis
S. Martinez-Yelamos et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Predictors of relapse rate in MS clinical trials
U Held et al.
NEUROLOGY (2005)